Anish Suri, President and Chief Scientific Officer, Cue Biopharma discusses their proprietary Immuno-STAT(tm)  platform. Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.  The company's proprietary platform Immuno-STAT(tm) (Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.  The company is currently conducting a Phase 1 study in HPV16-driven head and neck cancer and partnering with Merck to develop treatments for autoimmune diseases. @CueBiopharma #immunooncology  #HNSCC  #TCells CueBiopharma.com Download the transcript here